Compare VGAS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VGAS | LUNG |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Major Chemicals | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2M | 57.9M |
| IPO Year | N/A | 2020 |
| Metric | VGAS | LUNG |
|---|---|---|
| Price | $1.76 | $1.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 30.7K | ★ 377.5K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.92 | $1.13 |
| 52 Week High | $3.92 | $5.46 |
| Indicator | VGAS | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 53.08 |
| Support Level | $1.48 | $1.36 |
| Resistance Level | $2.08 | $1.93 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 66.66 | 86.82 |
Verde Clean Fuels Inc is a renewable energy company specializing in the conversion of synthesis gas, or syngas, derived from diverse feedstocks, such as biomass, MSW, and mixed plastics, as well as natural gas (including synthetic natural gas) and other feedstocks, into liquid hydrocarbons that can be used as gasoline through a proprietary liquid fuels technology, the STG process.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.